*The search scope is limited to the products and news section of this site
*The search scope is limited to the products and news section of this site
The "2024 China Biopharmaceutical Industry Chain Innovation Billboard" was officially announced during the Sixth Session China Biopharmaceutical Industry Innovation and Transformation International Summit & the First Guangdong-Hong Kong-Macao Greater Bay Area Biopharmaceutical Industry Innovation and Transformation Forum, grandly held in Guangzhou on December 17, 2024. Azvudine, independently developed by Genuine Biotech, was honored with the "Best Commercial Return Award (Chemical Drug)" for its outstanding performance during its three years on the market.
Recently, the People's Government of Henan Province issued the "Decisions on Science and Technology Awards of Henan Province in 2024", and granted the first prize of Henan Provincial Technical Invention Award to the project "development and application of the Class 1 innovative drug for the dual-target treatment of AIDS" of Azvudine.
On Nov. 28, Genuine Biotech announced that its self-developed Azvudine Tablets (trade name: Jiebeian®) has been successfully renewed in the 2024 National Reimbursement Drug List.
On Oct. 20, the Medical and Health Conference, one of the serial events celebrating the 10th anniversary of Zhongyuan Bank, was successfully held in Zhengzhou. At the conference, Genuine Biotech entered into a strategic cooperation agreement with Zhongyuan Bank, which signifies deepened bank-enterprise cooperation and anticipates to energize the innovation and development in the pharmaceutical industry with technology finance, thereby facilitating scientific & technological innovation and high-quality development of the industry.
Recently, the 2024 Misi Conference (China Medical and Health Industry Symbiosis Conference), organized by the industry's authoritative medical and health information platform MENET, was grandly held in Huzhou, Zhejiang, under the theme "Tenacity·Enlightenment of the New Stage". At the conference, the "2023 Top 100 Innovation List Series for Biopharmaceutical Enterprises in China" was officially released. Genuine Biotech once again made it to the "Top 30 Innovative Small-Molecule Pharmaceutical Enterprises in China", marking the third consecutive year since 2021 that the company has received this honor.
Looking back on 2023, Genuine Biotech achieved our expected operational targets, with the company's development thriving and advancing steadily.
The 36th "World AIDS Day" was celebrated on Dec. 1, 2023 under the theme "Let Communities Lead". Highly active antiretroviral therapy (HAART) has significantly improved the anti-HIV efficacy, contributing to a marked enhancement of patients' quality of life and prognosis.
Recently, China Times announced the prestigious list of 2023 Golden Cane Award winners in Beijing. Genuine Biotech, by virtue of its outstanding innovation capacity and pioneering R&D achievements, received the prize of "Top 10 Innovative Biotech Companies of the Year".
On Sep. 19, 2023, Genuine Biotech announced the appointment of Dr. James He as Senior Vice President and Chief Medical Officer (CMO). Dr. He will lead the clinical and registration team, and assume the responsibility for the product pipeline strategy, clinical project planning and operations, product registration and team construction.
Recently, the award ceremony for the "Henan Socially Responsible Enterprise of 2022 and Entrepreneur with Outstanding Social Contribution" was grandly held in Zhengzhou. Genuine Biotech was honored with the "2022 Annual Award of Henan Socially Responsible Enterprise".
Copyright © 2022 河南真实生物科技有限公司 All Rights Reserved 京ICP备2021026784号-1
